[1] 李慧君,胡桃红.急诊经皮冠状动脉介入治疗术后抗栓治疗个体化方案研究[J].中国医药,2013,8(3):307-309. [2] 马改改,杜苗苗,张栋铭,等.长期口服抗凝药治疗患者行经皮冠状动脉介入治疗术后应用华法林联合氯吡格雷二联抗栓治疗方案安全性及有效性的荟萃分析[J].中华医学杂志,2016,96(17):1377-1382. [3] Dvir D,Kitabata H,Waksman R. Large coronary thrombus: A safe and effective approach using percutaneous coronary intervention after vigorous antithrombotic therapy[J].Cardiovasc Rev Med,2013,S1553-8389. [4] Ghattas A,Shantsila E,Lip Gregory YH. Antithrombotic therapy after percutaneous coronary intervention in anticoagulated patients: a fine balance between thrombosis and bleeding[J].Ther Adv Cardiovasc Dis,2011,5(1):5-9. [5] Arora RR, Rai F. Antiplatelet intervention in acute coronary syndrome[J].Am Therapeutics,2008,16(5):1687-1688. [6] Gao F, Zhou YJ, Wang ZJ,et al. Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation[J].Circ J,2010, 74(4):701-708. [7] Cannon CP, Bhatt DL, Oldgren J,et al.Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation[J].N Engl J Med,2017, 377(16):1513. [8] Magdalena D. Balancing between bleeding and thromboembolism after percutaneous coronary intervention in patients with atrial fibrillation. Could triple anticoagulant therapy be a solution[J]?Postepy Kardiol Interwencyjnej,2013,9(3):234-240. [9] 马颖艳,王艳霞,徐白鸽,等.替格瑞洛用于经皮冠状动脉介入治疗术后患者抗血小板治疗短期内的有效性和安全性研究[J].中国介入心脏病学杂志,2014,14(6):380-383. [10] 张勇,王军,董志军,等.新型抗栓药替格瑞洛对急诊经皮冠状动脉介入治疗的近期疗效及安全性评价[J].中国心血管病研究,2014,12(6):543-546. [11] 刘文禹,俞晶晶,陈传品,等.心房颤动患者经皮冠状动脉介入治疗术后三联抗栓治疗的研究进展[J].中国临床药理学杂志,2017,33(12):1161-1164. [12] 李兴渊, 彭广操. 冠心病合并房颤患者PCI术后抗栓策略的探讨[J].医药论坛杂志, 2015(9):91-92. [13] Andrade JG, Deyell MW, Khoo C,et al.Risk of bleeding on triple antithrombotic therapy after percutaneous coronary intervention/stenting: a systematic review and meta-analysis[J].Can J Cardiol,2013,29(2):204-212. [14] 杨清波.冠心病合并心房颤动患者冠状动脉支架植入术后的抗栓治疗[J].临床荟萃,2013,28(3):339-341. [15] 李玲.冠心病合并心房颤动患者冠状动脉介入治疗术后抗栓治疗调查及随访[J].中国循环杂志,2007,22(3):166-168.
2019, Vol. 36 
